MAPT and Alzheimer disease: The pathological hallmarks of Alzheimer’s disease (AD) are amyloid-beta (Aβ) plaques and hyper-phosphorylated tau tangles.1 These, and other related neurodegenerative biomarkers, can be measured in CSF and blood, offering valuable insights into pathophysiology as well as clinical diagnosis, prognosis, and monitoring of AD and other dementias.